{"analyses":[{"ciLowerLimit":"0.49","ciNumSides":"TWO_SIDED","ciPctValue":"90","ciUpperLimit":"2.34","groupDescription":"Bayesian Emax model was used for statistical calculation. The posterior medians and 90% credible intervals (5th and 95th percentiles of the relevant posterior distribution) were reported for differences relative to placebo). No adjustments were made for multiplicity.","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY","paramType":"Difference in Posterior Median","paramValue":"1.33"},{"ciLowerLimit":"1.08","ciNumSides":"TWO_SIDED","ciPctValue":"90","ciUpperLimit":"3.15","groupDescription":"Bayesian Emax model was used for statistical calculation. The posterior medians and 90% credible intervals (5th and 95th percentiles of the relevant posterior distribution) were reported for differences relative to placebo). No adjustments were made for multiplicity.","groupIds":["OG000","OG002"],"nonInferiorityType":"SUPERIORITY","paramType":"Difference in Posterior Median","paramValue":"2.08"},{"ciLowerLimit":"1.68","ciNumSides":"TWO_SIDED","ciPctValue":"90","ciUpperLimit":"4.34","groupDescription":"Bayesian Emax model was used for statistical calculation. The posterior medians and 90% credible intervals (5th and 95th percentiles of the relevant posterior distribution) were reported for differences relative to placebo). No adjustments were made for multiplicity.","groupIds":["OG000","OG003"],"nonInferiorityType":"SUPERIORITY","paramType":"Difference in Posterior Median","paramValue":"3"}],"classes":[{"categories":[{"measurements":[{"comment":"Measure Type = Posterior Median = -0.60 Measure of Dispersion = 90% Credible Interval = -1.50 to 0.24","groupId":"OG000","lowerLimit":"NA","upperLimit":"NA","value":"NA"},{"comment":"Measure Type = Posterior Median = 0.75 Measure of Dispersion = 90% Credible Interval = 0.06 to 1.44","groupId":"OG001","lowerLimit":"NA","upperLimit":"NA","value":"NA"},{"comment":"Measure Type = Posterior Median = 1.48 Measure of Dispersion = 90% Credible Interval = 0.87 to 2.08","groupId":"OG002","lowerLimit":"NA","upperLimit":"NA","value":"NA"},{"comment":"Measure Type = Posterior Median = 2.39 Measure of Dispersion = 90% Credible Interval = 1.49 to 3.34","groupId":"OG003","lowerLimit":"NA","upperLimit":"NA","value":"NA"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"45"},{"groupId":"OG001","value":"46"},{"groupId":"OG002","value":"46"},{"groupId":"OG003","value":"50"}],"units":"Participants"}],"description":"Body weight was measured in kilograms using a calibrated weighing scale. Baseline was defined as the last average of the duplicate measurements prior to, or on Day 1. The average of the duplicate body weights collected at assessment time was considered. The posterior medians and 90 percent (%) credible intervals (5th and 95th percentiles of the relevant posterior distribution) were reported for each randomized dose (including placebo). 4-Parameter maximal effect (E max) model: change from baseline = E 0 + (E max \\* dose\\^Hill) / (ED 50\\^Hill + dose\\^Hill), where E0 is the placebo effect, E max is the maximum effect, ED 50 is the dose producing 50% of the maximum effect, and Hill is the slope parameter. Model utilized a Bayesian methodology with a robustified, informative meta-analytic predictive prior for the placebo change from baseline at week 12.","dispersionType":"90% Confidence Interval","groups":[{"description":"Part A: Participants were randomized to receive placebo matching to Ponsegromab SC Q4W up to 12 weeks (total of 3 doses).","id":"OG000","title":"Part A: Placebo"},{"description":"Part A: Participants were randomized to receive Ponsegromab 100 mg SC Q4W up to 12 weeks (total of 3 doses).","id":"OG001","title":"Part A: Ponsegromab 100 mg"},{"description":"Part A: Participants were randomized to receive Ponsegromab 200 mg SC Q4W up to 12 weeks (total of 3 doses).","id":"OG002","title":"Part A: Ponsegromab 200 mg"},{"description":"Part A: Participants were randomized to receive Ponsegromab 400 mg SC Q4W up to 12 weeks (total of 3 doses).","id":"OG003","title":"Part A: Ponsegromab 400 mg"}],"paramType":"MEDIAN","populationDescription":"Censored analysis set included all evaluable participants. For participants who discontinued study intervention, or received a prohibited procedure or prohibited medication, all observations post-discontinuation, or post-procedure, were censored and treated as missing data. For participants who missed a dose, or received an incomplete dose, all observations post-missed/incomplete dose were censored and treated as missing data.","reportingStatus":"POSTED","timeFrame":"Baseline, Week 12","title":"Part A: Change From Baseline in Body Weight at Week 12","type":"PRIMARY","unitOfMeasure":"Kilogram"}